An application of meta-analysis techniques in the evaluation of adverse experiences with antihypertensive agents

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 3, 1999, Pages 169-177

  Sakai, Hironori ^a   Hayashi, Kunihiko ^b   Origasa, Hideki ^c   Kusunoki, Tadashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Adverse experiences; Beta blockers; Calcium channel blockers; Diuretics; Drug safety profile; Hypertension; Meta analysis; Randomized controlled trials

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; EDEMA; HEADACHE; HOT FLUSH; HUMAN; MEDICAL INFORMATION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SIDE EFFECT;

EID: 0033038272     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199905/06)8:3<169::AID-PDS416>3.0.CO;2-F     Document Type: Article

References (37)

1. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch. Intern. Med. 1993; 153: 154-183.
2. Sakai, H., Hayashi, K., Origasa, H. et al. An overview of long-term randomized clinical trials on hypertension and the therapeutic guidelines. Jpn J. Clin. Pharmacol. Ther. 1995; 26(2): 637-650.
3. Held, P. H., Usuf, S. and Furberg, C. D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br. Med. J. 1989; 299: 1187-1192.
4. Yusuf, S., Held, P. and Furberg, C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT II) and other recent studies. Am. J. Cardiol. 1991; 67: 1295-1297.
5. Psaty, B. M., Heckbert, S. R., Koepsell, T. D. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
6. Furberg, C. D., Psaty, B. M. and Meyer, J. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
7. Pahor, M., Guralnik, J. M., Corti, M. C. et al. Long-term survival and use of antihypertensive medications in older persons. J. Am. Geriat. Soc. 1995; 43: 1191-1197.
8. Faich, G. A., Lawson, D. H., Tilson, H. H. et al. Clinical trials are not enough: drug development and pharmacoepidemiology. J. Clin. Res. Drug Devel. 1987; 1: 75-87.
9. DerSimonian, R. and Laird, N. Meta-analysis in clinical trials. Controlled Clin. Trials 1986; 7: 177-188.
10. Boulet, A. P., Chockalingam, A., Fodor, J. G. et al. Treatment of mild-to moderate hypertension: Comparison between a calcium-channel blocker and a potassium-sparing diuretic. J. Cardiovasc. Pharmacol. 1990; 18(suppl. 9): S45-S50.
11. Storm, T. L., Badskjaer, J., Hammer, R. et al. Tiapamil and hydrochlorothiazide: A double-blind comparison of two antihypertensive agents. J. Clin. Pharmacol. 1987; 27: 18-21.
12. Moser, M., Lunn, J. and Materson, B. J. Comparative effects of diltiazem and hydrochlorothiazide in blacks with systemic hypertension. Am. J. Cardiol. 1985; 56: 101H-104H.
13. Chiariello, M. et al. A double-blind comparison of the efficacy and safety of lacidipine and hydrochlorothiazide in essential hypertension. J. Cardiorasc. Pharmacol. 1991; 17(suppl. 4): S35-S37.
14. Fagan, T. C., Brown, R., Schnaper, H. et al. Nicardipine and hydrochlorothiazide in essential hypertension. Clin. Pharmacol. Ther. 1989; 45: 429-438.
15. Byyny, R. L., LoVerde, M. and Mitchell, W. Treatment of hypertension in the elderly with a new calcium channel blocking drug, nitrendipine. Am. J. Med. 1989; 86: 49-55.
16. Benjamin, N., Phillips, R. J. W. and Robinson, B. F. Verapamil and Bendrofluazide in the treatment of hypertension: A controlled study of effectiveness alone and in combination. Eur. J. Clin. Pharmacol. 1988; 34: 249-253.
17. Giles, T. D., Sander, G. E., Roffidal, L. C. et al. Comparison of nitrendipine and hydrochlorothia-zide for systemic hypertension. Am. J. Cardiol. 1987; 60: 103-106.
18. Gostick, N. K., Mayhew, S. R., Mukerji, D. et al. A randomised comparative trial of nicardipine versus amiloride and hydrochlorothiazide in mild to moderate hypertension. A report from the general practitioner hypertension study group. J. Hum. Hypertens. 1989; 3(2): 141-144.
19. Saito, I., Suzuki, H. and Saruta, T. Efficacy and safety of long-term drug therapy in essential hypertension. Japan Med. J. 1991; 3483: 28-31. (In Japanese.)
20. Yamazaki, N., Kokubu, T., Takeda, T. et al. Clinical effect of nisoldipine in essential hypertension. The Clinical Report 1988; 22: 4111-4134. (In Japanese.)
21. Watanabe, T., Yamazaki, N., Ogawa, K. et al. Clinical effect of atenolol on essential hypertension. Jpn Pharmacol. Ther. 1987; 15: 4183-4197. (In Japanese.)
22. Kokubu, T., Masuyama, Y., Ikeda, M. et al. Clinical effect of nifedipine on essential hypertension. J. Clin. Exp. Med. 1985; 132: 894-922. (In Japanese.)
23. Goto, Y., Iimura, O., Inagaki, Y. et al. Clinical effect of nifedipine on essential hypertension. Geriat. Med. 1983; 21: 1868-1900. (In Japanese.)
24. Fukui, T. and Okajima, S. Clinical effect of nifedipine and acebutolol on essential hypertension. Gendai Iryo 1983; 15: 1707-1712. (In Japanese.)
25. Cacciapuoti, F., Perrone, N., Diaspro, R., et al. Slowing of mitral valve annular calcium in systemic hypertension by nifedipine and comparisons with enalapril and atenolol. Am. J. Cardiol. 1993; 72: 1038-1042.
26. Saunders, E., Weir, M. R., Kong, W. et al. A comparison of the efficacy and safety of a beta blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch. Intern. Med. 1990; 150: 1707-1713.
27. M'Buyamba-Kabangu, J. R., Lepira, B., Fagard, R. et al. Relative potency of a beta blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur. J. Clin. Pharmacol. 1986; 29: 523-527.
28. M'Buyamba-Kabangu, J. R., Fagard, R., Lijnen, P. et al. Calcium entry blockade or beta blockade in long-term management of hypertension in blacks. Clin. Pharmacol. Ther. 1987; 41: 45-54.
29. Szlachcic, J., Hirsch, A. T., Tubau, J. F. et al. Diltiazem versus propranolol in essential hypertension: Responses of rest and exercise blood pressure and effects on exercise capacity. Am. J. Cardiol. 1987; 59: 393-399.
30. Amabile, G. and Serradimigni, A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: Comparative double-blind trial. Eur. Heart J. 1987; 8(suppl. M): 65-69.
31. Mengden, T., Schubert, M., Jeck, T. et al. Causal versus ambulatory twenty-four hour blood pressure measurement in a comparative study with bisoprolol or nitrendipine. J. Hypertension 1990; 8(suppl. 4): S91-S94.
32. Frishman, W. H., Brobyn, R., Brown, R. D. et al. A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension. J. Cardiovasc. Pharmacol. 1988; 12(suppl. 7): S103-S106.
33. Samizo, K., Hamada, C., Ishikura, C. et al. A 10-year study on antihypertensive drug use based on prescription data in Bohsei pharmacy. Jpn. J. Pharmacoepidemiol. 1996; 1(2): 107-115. (in Japanese).
34. Hayashi, K. and Walker, A. M. Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Controlled Clin. Trials 1996;17:99-110.
35. Messerli, F. H. What, if anything, is controversial about calcium antagonists. Am. J. Hypertens. 1996; 9: 177S-181S.
36. Staessen, J. A. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350(9080): 757-764.
37. Hansson, L. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351(9118): 1755-1762.